Aldeyra Therapeutics Inc (NASDAQ:ALDX) has been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $19.60.
ALDX has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 26th. Seaport Global Securities initiated coverage on shares of Aldeyra Therapeutics in a research note on Friday, January 26th. They issued a “buy” rating and a $13.00 target price for the company. ValuEngine upgraded shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, March 13th. Finally, Cantor Fitzgerald set a $23.00 target price on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Thursday.
Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new position in shares of Aldeyra Therapeutics in the third quarter valued at approximately $134,000. Woodstock Corp raised its position in Aldeyra Therapeutics by 20.4% in the 4th quarter. Woodstock Corp now owns 58,243 shares of the biotechnology company’s stock worth $396,000 after purchasing an additional 9,850 shares during the last quarter. Geode Capital Management LLC raised its position in Aldeyra Therapeutics by 34.6% in the 4th quarter. Geode Capital Management LLC now owns 102,263 shares of the biotechnology company’s stock worth $695,000 after purchasing an additional 26,269 shares during the last quarter. Mangrove Partners bought a new position in Aldeyra Therapeutics in the 4th quarter worth approximately $1,118,000. Finally, Vanguard Group Inc. raised its position in Aldeyra Therapeutics by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares during the last quarter. Institutional investors own 51.17% of the company’s stock.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, March 29th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.04). equities research analysts expect that Aldeyra Therapeutics will post -1.43 EPS for the current fiscal year.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.